Medicinova, Inc.

Columbia University

Medicnova, Inc.

Kazuko Matsuda

Yuichi Iwaki

Kenneth Walter Locke

Richard E Gammans

Michael E Kalafer

Federico Carlos Aréjola Gaeta

Kerrie McDonald

Kirk William Johnson

Gary K Schwartz

Grazia Ambrosini

Kale Ruby

Alex J Rai

Masatsune Ogura

Described herein are methods for decreasing triglyceride synthesis and/or decreasing triglyceride accumulation in the liver of a subject, wherein the methods comprise administering to the subject a compound of Formula (I): a metabolite thereof, or a pharmaceutically acceptable salt thereof.

Methods to decrease triglyceride synthesis in the liver

Disclosed is a method of reducing plasma level of macrophage migratory inhibitory factor in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

Methods of reducing plasma level of macrophage migratory inhibitory factor in patients

Disclosed is a method of treating post-COVID condition(s) in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

Methods of treating post-COVID condition(s)

A method of preventing metastasis of a cancer in a patient in need thereof includes administering to the patient a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

Methods of minimizing cancer metastasis

Methods of preventing cancer metastasis

Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).

Treatment of progressive neurodegenerative disease with ibudilast

A method of treating chemical-induced lung injury in a subject in need thereof includes administering to the subject a therapeutically effective amount of ibudilast, or a pharmaceutical salt thereof.

Methods of treating chemical gas exposure

This disclosure is directed to ibudilast higher dosage oral formulations, such as tablet or capsule formulations, and the corresponding methods of treatment.

Ibudilast oral formulations and methods of using same

Methods and dosing regimens for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof and at least one or more other therapeutic agent.

Methods and dosing regimens using ibudilast and a second agent for cancer therapy

The present disclosure relates generally to methods for treating neurodegenerative diseases, including their progressive forms. In particular, the present disclosure pertains to methods of treating or preventing neurodegenerative diseases, including their progressive forms and their associated symptoms by administering a combination of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) and riluzole, or pharmaceutically acceptable salts of one or both thereof.

Combination of ibudilast and riluzole and methods of using same

This disclosure is directed to methods of treating ophthalmic disease/disorder or injury associated with neurodegenerative disease/disorder, such as progressive multiple sclerosis, or a neuro-ophthalmologic disorder in human patients using ibudilast.

Methods of treating ophthalmic disease/disorder or injury with ibudilast

This disclosure is directed to methods of alleviating the negative effects of, treating, or slowing the progression of progressive multiple sclerosis in human patients using ibudilast and interferon-beta.

Combination of ibudilast and interferon-beta and methods of using same

Compositions and methods for treating glioblastoma or recurrent glioblastoma and its associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine) or a pharmaceutically acceptable salt thereof.

Growing community of inventors

Beverly Hills, CA, United States of America

Kazuko Matsuda